---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037322"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:14:14.726948+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%

## Summary
- Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.
- Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.
- Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).
- XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.
- Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts.

## SEC filing metadata
- accession: 0001140361-24-037322
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/0001140361-24-037322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/ef20034059_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037322
- JSON: https://secwatch.observer/filing/0001140361-24-037322.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.